Tenocytes serve to synthesize and maintain collagen fibrils and other matrix proteins in tendon. The underlying biological mechanisms of postnatal tendon growth and repair are not well understood. Insulin-like growth factor 1 (IGF1) plays an important role in the growth and remodeling of numerous tissues, but less is known about IGF1 in tendon. We hypothesized that IGF1 signaling is required for proper tendon growth in response to mechanical loading through regulation of collagen synthesis and cell proliferation. We conditionally deleted the IGF1 receptor (IGF1R) in scleraxis (Scx) expressing tenocytes, and compared to control Scx:IGF1R + mice, Scx:IGF1R Δ mice demonstrated reduced tenocyte proliferation and smaller tendons in response to mechanical loading. Additionally, we identified that both the PI3K/Akt and ERK pathways are activated downstream of IGF1 and interact in a coordinated manner to regulate cell proliferation and protein synthesis.
Introduction
Tendon is a dense connective tissue that serves to transmit force from muscle to bone during mechanical loading. The tendon extracellular matrix (ECM) is composed mostly of type I collagen, as well as type III collagen, elastin, and proteoglycans . Tendon fibroblasts, or tenocytes, are the main cell type in tendon and are responsible for the synthesis, organization, and maintenance of the ECM (Wang, 2006) .
In response to high stress repetitive mechanical loading, such as that which occurs during resistance exercise, tendons adapt by undergoing hypertrophy (Couppé et al., 2008) . This results in an increase in tendon crosssectional area (CSA) through an induction of cell proliferation and collagen production (Geremia et al., 2018; Gumucio et al., 2014; Svensson et al., 2016) . Repetitive loading can also induce a chronic inflammatory condition referred to as tendinopathy (Mead et al., 2018; Millar et al., 2017) . Despite the high prevalence of tendon injury and overall importance of tendon in maintaining musculoskeletal health, the underlying biological mechanisms that regulate postnatal growth are not well understood. Further, as tendinopathy is thought to arise due to improper responses to mechanical stimuli, gaining a greater understanding of the basic biological mechanisms of tendon growth could help develop new therapies for the treatment of tendon disorders.
Insulin-like growth factor-1 (IGF1), which can be induced by growth hormone (GH) and other mechanical signals, is an integral component of the growth and development of several different tissues (Heinemeier et al., 2012) . IGF1 is typically bound to an IGFBP carrier protein, and upon proteolytic degradation of the IGFBP, IGF1 is liberated and can interact with its receptor, IGF1R which is a member of the receptor tyrosine kinase (RTK) family of transmembrane receptors (Lelbach et al., 2005) . IGF1 is a potent activator of skeletal muscle cell proliferation and protein synthesis, and the deletion of IGF1 in muscle fibers results in fiber atrophy and disrupted metabolism (Heinemeier et al., 2012; Vassilakos et al., 2019) . In bone, overexpression of IGF1 results in increased bone mineral density, and the inactivation of IGF1R in osteoblasts impairs matrix mineralization (Yakar et al., 2010) . However, the role of IGF1 in tendon growth has not been fully examined. Previous studies in tendon have revealed an increase in tendon collagen synthesis following IGF1 treatment in engineered tendon tissue and healthy human tendon, as well as in horses with tendinopathies (Dahlgren et al., 2002; Herchenhan et al., 2015; Nielsen et al., 2014b) . Given the role that IGF1 plays in the growth of other tissues, and observations of increased IGF1 expression correlated with enhanced ECM production in tendons, we sought to determine the mechanisms behind IGF1-mediated tendon growth. We hypothesized that IGF1 signaling is required for proper tendon growth in response to mechanical loading through a coordinated induction of collagen synthesis and cell proliferation. To test this hypothesis, we induced tendon growth in adult mice via mechanical overload of the hindlimb, and deleted IGF1R in scleraxis expressing tenocytes. Additionally, we performed a series of in vitro experiments where we treated tenocytes with IGF1 for various durations to examine the molecular mechanisms induced by IGF1 during postnatal tendon growth.
Results
We generated mice that enabled us to perform a targeted deletion of IGF1R in tenocytes by crossing IGF1R flox/flox mice in which exon 3 of IGF1R is flanked by loxP sites (Dietrich et al., 2000) , to Scx CreERT2/CreERT2 mice in which an IRES-CreERT2 sequence is present between the stop codon and 3' UTR in exon 2 of scleraxis (Howell et al., 2017) . After performing initial crosses between Scx CreERT2/CreERT2 and IGF1R flox/flox mice, mice were backcrossed until a homozygous state was reached. Scx CreERT2/CreERT2 :IGF1R flox/flox mice allowed us to inactivate IGF1R in scleraxis expressing cells upon treatment with tamoxifen (referred to as Scx:IGF1R Δ mice), while Scx +/+ :IGF1R flox/flox mice would maintain the expression of IGF1R in scleraxis expressing cells after tamoxifen treatment (referred to as Scx:IGF1R + mice). An overview of the alleles used in this study is provided in Figure 1A . Wild type C57BL/6J mice were used for cell culture experiments, while Scx:IGF1R + and Scx:IGF1R Δ mice were used in whole animal studies.
To study the role of IGF1 signaling in adult tendon hypertrophy, we treated mice with tamoxifen, and then induced a mechanical overload in plantaris tendons of Scx:IGF1R + and Scx:IGF1R Δ mice, and analyzed tendons at either 7 or 14 days after creation of the growth stimulus ( Figure 1A -C). Tamoxifen treatment resulted in an over 90% reduction in IGF1R expression in Scx:IGF1R Δ mice compared to Scx:IGF1R + mice at both 7 and 14 days ( Figure 1D ). We then analyzed histological changes in plantaris tendons. As previously observed in other models of synergist ablation-mediated mechanical overload, a neotendon tissue formed around the original tendon that matured and filled in with collagen over time, however growth was blunted in the Scx:IGF1R Δ mice (Figure 2A -D). The total tendon CSA was not different between groups at 7 days, but by 14 days the total CSA of Scx:IGF1R + mice was twice as large as Scx:IGF1R Δ mice ( Figure 2D ). This occurred due to a greater expansion of the neotendon of Scx:IGF1R + mice over time, while Scx:IGF1R Δ mice displayed no change between 7 and 14 days ( Figure 2C ). No differences in cell density were observed in the original tendon, neotendon, or total tendon across time or genotype ( Figure 2E -G), however the percentage of proliferating cells was two-fold greater in the neotendon of Scx:IGF1R + mice compared to Scx:IGF1R Δ mice ( Figure 2H -J).
We then sought to identify changes in the transcriptome of plantaris tendons of Scx:IGF1R + mice and Scx:IGF1R Δ mice in response to mechanical overload using RNAseq. At 7 days, there were 1108 transcripts that were at least 50% differentially regulated between genotypes, but only 159 transcripts at 14 days ( Figure   3A -B). Pathway enrichment analysis was performed to evaluate cellular functions and signaling pathways predicted to be different between groups over time. Several of the pathways identified were involved with growth and differentiation, cytoskeletal signaling, and ECM production ( Table 1) . We selected several genes related to these processes to further explore and report in Figure 3C -E, and also performed qPCR validation of a subset of relevant genes ( Table 2 ). Compared to non-overloaded controls, several growth factors and signaling molecules including Adam12, Bmp1, Ctsd, Igf1, and Pappa were upregulated in all overloaded groups, while Bmp6, Fgf2, Inhbb, and Vegfa were downregulated at all time points ( Figure 3C ). There was also an upregulation in Bmp1, Bmp6, Igf1, Inhba, Pdgfa, Pdgfb, Tgfb1, Tgfb2, Wnt5b, and Wnt9a in 7 day Scx:IGF1R Δ mice compared to 7 day Scx:IGF1R + mice, and by 14 days Fgf2 and Tgfb2 were significantly higher in Scx:IGF1R Δ mice ( Figure 3C ). For genes involved in the liberation of IGF1 from IGFBPs, C1s2 was upregulated at 7 days and Ctsd was upregulated at 14 days in Scx:IGF1R Δ mice, while no differences in Pappa were observed between genotypes ( Figure 3C ). With regards to cell proliferation, and tenocyte specification and differentiation, Acta2, Ccna2, Ccnb1, Ccne1, Cdk1, Cdk2, Cdk4, Cdk6, Cfi1, Itgav, Mki67, Pcna, Ptk2, Snai1, Trp53, and Vim were upregulated in all overloaded groups ( Figure 3D ). Cdkn1b, Itgb3, Rerg, S100a4, Scx, Snai1, and Yap1 were upregulated in 7 day Scx:IGF1R Δ mice compared to 7 day Scx:IGF1R + mice, while Acta2, Cfl1, Itgav, Mcm6, and Pcna were downregulated ( Figure 3D ). At 14 days, Rerg and Scx were upregulated in Scx:IGF1R Δ mice ( Figure 3D Figure 3E ).
Based on the in vivo results which suggested a role for IGF1 in controlling cell cycle behavior and ECM synthesis involving PI3K/Akt and ERK signaling, we took a reductionist approach to evaluate IGF1 signaling in vitro using cultured primary tenocytes. We observed that IGF1 treatment resulted in IGF1R Y1135 phosphorylation, leading to early downstream activation of IRS1 Y608 , ERK1/2 T202/Y204 , Akt T308 , Akt S473 , p70S6K T389 , and p70S6K T421/S424 ( Figure 4A ). While ERK1/2 T202/Y204 , Akt T308 , and Akt S473 phosphorylation decreased following 5 minutes of IGF1 treatment, p70S6K T389 and p70S6K T421/S424 activation was sustained from 15 through 60 minutes after treatment, and phosphorylation of ELK1 S383 was detected at 30 and 60 minutes ( Figure 4A ). Phosphorylation of the inhibitory IRS1 S612 site was detected at 30 and 60 minutes following IGF1 treatment ( Figure 4A ).
To further explore the effect of IGF1 treatment on tenocytes, we performed RNAseq using cultured tenocytes that were not treated with IGF1, or treated with IGF1 for 1, 2, 6, or 24 hours. At 1 hour, over 400 transcripts were at least 50% differentially regulated and had a q<0.05, while over 1000 genes were similarly affected at 2, 6, and 24 hours ( Figure 4B ). We used the same panel of genes explored in whole tendons for further analysis in cultured tenocytes. Across these transcripts, Egf, Mmp2 ,Tnmd, Trp53, Vim, and Yap1 were not affected by IGF1 treatment ( Figure 4C -E). For the growth factors and signaling molecules that were differentially regulated in whole tendons of Scx:IGF1R + and Scx:IGF1R Δ mice, there was an induction of Fgf2, Pdgfa, Pdgfb, Tgfb1, and Wnt9a by 2 hours, while Igf1 was downregulated compared to untreated cells ( Figure   4C ). By 24 hours, with the exception of Bmp1 and Tgfb2, nearly all other growth factors and signaling molecules that were differentially regulated in tendons were downregulated in cultured tenocytes ( Figure 4C ). Cfl1, Itgb3, Pcna, Scx, and Snai1 demonstrated an early upregulation in response to IGF1 treatment, while Acta2 and Cdkn1b were initially reduced ( Figure 4D ). By 24 hours Mcm6, Pcna, and S100a4 were upregulated and Acta2 was suppressed ( Figure 4D ). The ECM genes Mgp, Mmp3, Spp1, Timp1, and Tnc were upregulated by 2 hours, while Bgn, Col1a1, Col1a2, Ctgf, Cyr61, and Smoc2 were downregulated ( Figure 4E ). At 24 hours, Col3a1, Col5a1, Has2, Mgp, and Mmp14 were induced, and Bgn and Comp were reduced in IGF1 treated tenocytes.
As we observed differences in cell proliferation in vivo and that IGF1 affected the expression of cell cycle control genes in vitro, we next determined if IGF1 directly impacts the proliferation of cultured tenocytes, and the role of the PI3K/Akt and ERK pathways in this process. We sought to validate the findings for Mki67 expression in RNAseq data, and using qPCR we observed a slightly greater than 1.5-fold transient induction at 2 hours after IGF1 treatment, and a near 8-fold induction in Mki67 at 24 hours ( Figure 5A ). In support of these findings, we observed a 2.5-fold increase in the number of BrdU + tenocytes in response to IGF1 treatment ( Figure 5B ). Inhibiting the PI3K/Akt pathway with wortmannin did not impact IGF1-mediated tenocyte proliferation or Mki67 expression, while blocking ERK1/2 T202/Y204 with PD98059 reduced cell proliferation and Mki67 expression ( Figure 5B -C).
Based on the differences in tendon size between Scx:IGF1R + and Scx:IGF1R Δ mice, the differential expression of Col1a1 and Col1a2 in whole tendons, and the cell culture RNAseq data, we sought to determine whether IGF1 directly induces type I collagen expression in tenocytes. Using qPCR, there were no differences in Col1a1 and Col2a2 expression following treatment with IGF1 ( Figure 6A -B). We also did not observe doseor time-dependent effects of IGF1 on type I collagen protein abundance in tenocytes, although we did note that cells that are in the S phase, as indicated by the presence of EdU + nuclei, reduce type I collagen production ( Figure 6C -E).
Finally, we sought to determine the effect of IGF1 signaling on general protein synthesis. Using the SUnSET method in which the tyrosyl-tRNA analog puromycin is incorporated into newly synthesized proteins, we treated tenocytes with IGF1 and observed a 2-fold increase in puromycin incorporation. The broad spectrum translation inhibitor cycloheximide as well as wortmannin blocked IGF1-mediated protein synthesis in tenocytes, but surprisingly ERK1/2 inhibition resulted in a nearly 6-fold increase in protein synthesis ( Figure   7A -B). To investigate this phenomenon in more detail, we probed for the presence of permissive and inhibitory phosphorylation sites on components of the PI3K/Akt and ERK1/2 signaling pathways. As anticipated PD98059 blocked ERK1/2 T202/Y204 phosphorylation as well as phosphorylation of the downstream transcription factor ELK1 S383 , and wortmannin inhibited Akt T308 phosphorylation ( Figure 7C ). However, inhibition of ERK1/2 surprisingly increased Akt T308 phosphorylation independent of IRS1 Y608 phosphorylation, suggesting ERK1/2 is acting to inhibit protein synthesis downstream of IRS1 ( Figure 7C ). Further, wortmannin decreased ERK1/2 T202/Y204 and ELK1 S383 phosphorylation and abolished phosphorylation of the inhibitory IRS1 S612 site, leading to increased phosphorylation of the permissive IRS1 Y608 site ( Figure 7C ). Based on these findings, we propose a model in which IGF1 regulates tenocyte proliferation and protein synthesis through coordinated and intersecting actions of the PI3K/Akt and ERK1/2 pathways ( Figure 8 ).
Discussion
IGF1 is known to play a critical role in the growth and adaptation of various musculoskeletal tissues, including skeletal muscle, bone, and cartilage, but less is known about tendon. To study tendon growth we used the synergist ablation technique, in which the Achilles tendon is surgically removed resulting in a supraphysiological growth stimulus to the synergist plantaris tendon and muscle (Gumucio et which is involved in fibroblast-mediated tissue growth (Kalluri and Weinberg, 2009 ). Futher, we identified that both the PI3K/Akt and ERK pathways are activated downstream of IGF1, and work in a coordinated manner to regulate cell proliferation and protein synthesis. These results have important implications for our understanding of the basic biology of tendon growth and may inform the treatment of tendinopathies.
Numerous growth factors have been studied in the context of tenocyte proliferation in vitro. In the current study, we observed a minor increase in markers of cell proliferation within two hours of IGF1 treatment, but did not see notable increases until 24 hours. In mechanically stimulated tendons cell proliferation was reduced at 7 days in Scx:IGF1R Δ mice. The CSA of tendons was similar between mice at 7 days, but there was no appreciable growth in the tendons of Scx:IGF1R Δ mice between 7 and 14 days, while the tendons of Scx:IGF1R + mice continued to grow thereafter. This suggests that IGF1 is regulating tenocyte proliferation in an indirect manner, perhaps through controlling the expression of other growth factors and signaling molecules that directly regulate cell cycle machinery. TGFβ1 signals through the TGFβRII and TGFβRI receptors to fibroblast growth and proliferation also through RTK signaling, and in human renal fibroblasts, treatment with TGFβ1 increased cell proliferation through induction of FGF2 expression (Strutz et al., 2001) . In our data, the expression of TGFβ1, PDGFa, PDGFb, and FGF2 was upregulated by 2 hours following IGF1 treatment in cultured tenocytes, which corresponded to modest increases in Fos, Jun, Mki67, Pcna, cyclin E (Ccne1), Cdk2, and Cdk6, along with a decrease in p27 (Cdkn1b). By 24 hours, Bmp6 which inhibits cell proliferation ( Several cyclins (Ccna2, Ccnb1, and Ccne1) and CDKs (Cdk1, Cdk2, Cdk4, and Cdk6) were also upregulated, and a downregulation in p27 was observed. At the whole tissue level, Bmp6 was elevated and Pcna was decreased at 7 days in Scx:IGF1R Δ mice compared to Scx:IGF1R + mice, and several other growth factors and signaling molecules with direct roles in regulating cell proliferation were also differentially regulated.
Therefore, it is likely that IGF1 chiefly acts in an indirect manner to regulate tenocyte proliferation through the regulation of other growth factors that act loacally. The delayed effect of IGF1 on enhancing tenocyte proliferation may explain why the size of the neotendon was not different between Scx:IGF1R + and Scx:IGF1R Δ mice at 7 days, but at 14 days the neotendon of the Scx:IGF1R + mice was two-fold larger than Scx:IGF1R Δ mice.
In addition to reducing cell proliferation, the loss of IGF1R in tenocytes resulted in smaller tendons of mechanically loaded mice. Since type I collagen is the major constituent of the tendon ECM, and previous studies have demonstrated that direct injection of IGF1 into tendons increases collagen synthesis (Hansen et al., 2013 ) and patients with acromegaly that have elevated levels of IGF1 also demonstrate an upregulation of Col1a1 in their tendons , we sought to determine whether IGF1 could directly regulate collagen synthesis in tenocytes. Based on these studies, we anticipated that IGF1 would directly induce type I collagen expression and that Scx:IGF1R Δ mice would have reduced expression in their tendons in response to mechanical overload. However, Col1a1 and Col1a2, as well as Col3a1 and Col5a1, were upregulated in Scx:IGF1R Δ mice compared to Scx:IGF1R + mice, and treatment of tenocytes with IGF1 did not induce Col1a1 or Col1a2 expression and resulted in no change in type I procollagen protein abundance. These results indicate that IGF1 does not directly induce type I collagen gene expression nor increase type I collagen translation. In support of our observations of a delayed growth defect in tendons of Scx:IGF1R Δ mice, 3-dimensional tissue engineered tendon constructs treated with IGF1 demonstrated increased size and hydroxyproline content, but this increase was not observed until at least two weeks after beginning treatment with IGF1 (Herchenhan et al., 2015) . Numerous other genes that encode minor but important proteins that constitute or modify the ECM such as Ctgf, Fn, Mmp2, Mmp3, Mmp14, Postn, Smoc2, Spp1, Thsb4, Timp1, Tnc, Tnmd, Vcan, and Wisp1 were induced by mechanical loading of tendons, and Ctgf, Cyr61, Has2, Postn, Spp1, Thbs4, Timp1, Tnc, and Vcan appeared to be directly or indirectly regulated by IGF1 in cultured tenocytes.
To further explore the difference in size between tendons of Scx:IGF1R + and Scx:IGF1R Δ mice, we determined whether IGF1 regulated general protein synthesis. IGF1 is known to activate the PI3K/Akt pathway which increases protein synthesis in skeletal muscle , and local IGF1 can increase protein fractional synthesis rate in tendons of elderly men and patients with Ehlers-Danlos syndrome (Nielsen et al., 2014b; 2014a) . Using the SUnSET technique (Goodman and Hornberger, 2013; Goodman et al., 2011), we observed that treating tenocytes with IGF1 doubled protein synthesis rates, and blocking Akt phosphorylation returned protein synthesis levels to baseline. Based on these findings and our observations of IGF1 and type I collagen synthesis, we propose that the larger tendons in the Scx:IGF1R + mice occurred in part due to an increase in overall protein synthesis compared to Scx:IGF1R Δ mice, rather than a direct increase in collagen production. There are also other signaling molecules regulated by IGF1 or mechano-sensing pathways in whole tissue that influence collagen production. Further, the regulation of Col1a1 and Col1a2 translation is a complex process. While translation requires that active ribosomes bind to Col1a1 and Col1a2 mRNAs, translation initiation also requires the interaction of regulatory cofactors with the 5' stem loop and 3' untranslated region of the transcripts, and the binding of these transcripts to nonmuscle myosin and association with vimentin filaments (Stefanovic, 2013) . Combined, our results indicate that IGF1 signaling contributes to protein synthesis in tenocytes through an Akt-dependent mechanism, but IGF1 does not appear sufficient to induce type I collagen translation and likely works in a coordinated fashion with other signaling pathways to regulate this process.
ERK is a well-known signaling pathway that is activated in response to mechanical loading, often through the integrin αV/β3/FAK pathway (Tahimic et al., 2013) . In whole tendons, integrin αV (Itgav) and β3 (Itgab3) were induced in response to synergist ablation, and RNAseq pathway enrichment analysis predicted activation of integrin, FAK, and ERK pathways, with a differential response between Scx:IGF1R + and phosphorylation. We also observed that ELK1 S383 phosphorylation was inhibited by blocking PI3K. In other cell types, the PI3K pathway can amplify ERK T202/Y204 phosphorylation through activating the MAP3K RAF (Ebi et al., 2013) , and based on our results, there is likely a similar mechanism occurring in tenocytes.
In addition to promoting cell proliferation, IGF1 also increased protein synthesis by approximately twofold in tenocytes, and this process was dependent upon PI3K/Akt activation. However, inhibiting ERK T202/Y204 phosphorylation resulted in a nearly six-fold induction in protein synthesis, which was also a phenomenon that was not anticipated since ERK activation is often associated with mild increases in protein synthesis. This lead us to look at potential interactions between the PI3K/Akt and ERK pathways. IGF1R phosphorylates IRS1 Y608 , which is the principal site of interaction between IRS1 and the SH2 domain of PI3K. This causes the localization of PI3K to the plasma membrane where it can catalyze the conversion of PIP2 into PIP3 (Gumucio and Mendias, 2013) . Akt then binds membrane-bound PIP3 through an N-terminal pleckstrin homology (PH) domain, and is activated by PDK1. The recruitment of Akt to the membrane and the phosphorylation of Akt T308 through PDK1 allows Akt to be released into cytosol to activate mTOR, p70S6K, and other downstream effectors (Gumucio and Mendias, 2013) . IRS1 can also be phosphorylated at S612, which blocks phosphorylation of its own Y608 residue, and therefore IRS1 S612 phosphorylation inhibits the ability of IRS1 to activate PI3K (De Fea and Roth, 1997). In some cell types, p-ERK T202/Y204 can phosphorylate IRS1 S612 (Andreozzi et al., 2004 ; De Fea and Roth, 1997), however we did not observe this response in tenocytes.
Instead, p-ERK T202/Y204 appears to modulate protein synthesis downstream of IRS1, by inhibiting phosphorylation of Akt T308 either directly or by targeting a process downstream of IRS1 Y608 . This inhibitory role of ERK on the PI3K pathway explains the pronounced increase in protein synthesis when ERK signaling is inhibited. While p-ERK T202/Y204 did not play a role in IRS1 S612 or IRS1 Y608 phosphorylation, inhibition of Akt activation abolished IRS1 S612 phosphorylation and increased IRS1 Y608 phosphorylation, suggesting that Akt or a downstream effector molecule acts to negatively regulate the PI3K pathway at IRS1. Previous studies have indicated that p70S6K T389 can phosphorylate several inhibitory serine residues on IRS1 (Copps and White, 2012), and we propose that p70S6K T389 is acting in a similar way to phosphorylate IRS1 S612 and provide feedback inhibition on IGF1-mediated PI3K/Akt activation in tenocytes. Combined, these results indicate that the PI3K/Akt and ERK pathways interact downstream of IGF1 to control tenocyte proliferation and protein synthesis.
There are several limitations to this study. We only included male mice, and additional experiments evaluating the role of sex will likely provide further insight into the role of IGF1 in tendon adaptation. The plantaris overload synergist ablation technique used in this study is a supraphysiological growth stimulus that exceeds the normal growth signals tendons experience with exercise training. We only evaluated through two weeks after mechanical overload, and it is likely that IGF1 continues to have an influence on neotendon matrix growth and maturation beyond this point. Tendon mechanical properties were not assessed in this study, which limits interpretations about functional changes in mechanically overloaded tendons. We focused our analysis on the PI3K/Akt and ERK pathways based on the bioinformatics results, but it is likely IGF1 also regulates other downstream pathways in tenocytes. IGF1R was not completely abolished in tendons as cells other than tenocytes may also express this receptor. Despite these limitations, we feel that this study provided novel insight into the role of IGF1 signaling in regulating tendon growth. Figure 1B -C. The Achilles tendon was surgically excised to prevent the gastrocnemius and soleus muscles from plantarflexing the talocrural joint, resulting in compensatory hypertrophy of the adjacent synergist plantaris muscle and tendon. A small incision was created in the skin above the posterior paw plantarflexor tendons, and the Achilles tendon was isolated and excised, leaving stumps at the myotendinous junction and calcaneus. The skin was closed with GLUture (Zoetis, Kalamazoo, MI, USA), buprenorphine was administered for post-operative analgesia, and ad libitum weightbearing and cage activity were allowed in the postoperative period. Mice were closely monitored during the postoperative period for any adverse reactions. At tissue harvest, the left plantaris tendons were divided into proximal and distal halves, and snap frozen at -80ºC for gene expression analysis, while the right plantaris tendons were used for histology. After the tendons were removed, mice were euthanized by cervical dislocation.
Plantaris tendons from additional non-overloaded Scx:IGF1R + mice were obtained as described above for gene expression analysis.
Histology. Histology was conducted as previously described (Gumucio et al., 2014; Sugg et al., 2018) .
Plantaris tendons obtained from animals were immediately placed in 30% sucrose solution for one hour, snap frozen in Tissue-Tek OCT Compound (Sakura Finetek, Torrance, CA, USA) and stored at -80°C until use.
Tendons were sectioned at a thickness of 10 µm in a cryostat. Sections were stained with hematoxylin and eosin (H&E) to determine tendon cross-sectional area (CSA) and cell density. To evaluate proliferating cells, tendon sections were fixed in 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, blocked with 5% goat serum, and incubated with rabbit anti-Ki67 antibodies (1:100; ab16667, Abcam, Cambridge, MA, USA) and goat anti-rabbit antibodies conjugated to AF555 (1:300; A-21429, Thermo Fisher Scientific), as well as wheat germ agglutinin (WGA) lectin conjugated to Alexa Fluor 488 (AF488) (1:200; W11261, Thermo Fisher Scientific, Carlsbad, CA, USA) to identify the extracellular matrix, and DAPI (1:500; Sigma) to label nuclei.
Slides were imaged using an BX-51 microscope and camera (Olympus, Center Valley, PA, USA) for the H&E slides, while a A1 confocal laser microscope (Nikon Instruments, Tokyo, JP) was used for the Ki67 slides.
Quantification of tendon size and cell density was performed using ImageJ (NIH, Bethesda, MD, USA). In Vitro IGF1 Cell Culture Time Course. Tenocytes were grown to 60% confluence in GM, and switched to medium containing DMEM with 2% horse serum (Gibco) and 1% antibiotic-antimycotic (Gibco), referred to as differentiation medium (DM) overnight. The next day, media was replaced with DM containing 100ng/mL of IGF1 (R&D Systems, Minneapolis, MN, USA) for a period of time ranging from 1, 2, 6, or 24 hours. Cells that underwent the same procedure but did not receive IGF1 treatment are referred to as 0 hour cells. At the end of the treatment period RNA was isolated as described below.
In Vitro Signal Transduction Assays. Tenocytes were grown to 90% confluence in GM and serum starved in DMEM with 1% AbAm for three hours, followed by treatment with either the mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) inhibitor PD98059 (50 µM; InvivoGen, San Diego, CA, USA) to block ERK1/2 activation, or the PI3K inhibitor wortmannin (10 µM; InvivoGen) to inhibit Akt activation for 1 hour. Cells were then treated with 100ng/mL IGF1 for 5, 15, 30, or 60 minutes, scraped from their dishes and homogenized in RIPA buffer (Thermo Fisher Scientific) containing 1% protease and phosphatase inhibitors (Thermo Fisher Scientific).
In Vitro Proliferation. Cell proliferation as measured by the uptake of bromodeoxyuridine (BrdU) was measured as previously described (Sugg et al., 2018) . Tenocytes at 50% confluence were incubated overnight in DM, and then treated with DM containing 100 ng/ml of IGF1 (R&D Systems, Minneapolis, MN, USA), PD98059 (50 µM; InvivoGen), or wortmannin (10 µM; InvivoGen). Following a 16 hour overnight incubation, fresh media was added along with 20 µM of BrdU (Sigma) for one hour. After treatment with BrdU, cells were fixed in ice-cold methanol, permeabilized with 0.5% Triton X-100, and the BrdU epitope was exposed by denaturing DNA with 2 M HCl. Cells were then incubated with anti-BrdU antibodies (1:50; G3G4, Developmental Studies Hybridoma Bank, Iowa City, IA, USA) and secondary antibodies conjugated to AF555 (1:200; A-21127, Thermo Fisher Scientific), and DAPI (1:500) to identify nuclei. The number of BrdU + nuclei as a fraction of total nuclei were quantified in five randomly selected fields of a single experiment from four independent experiments performed per group. Plates were imaged in an EVOS FL microscope (Thermo Fisher Scientific) and quantified with ImageJ software.
In Vitro SUnSET Labeling. Protein synthesis in cultured tenocytes was measured using a surface sensing of translation (SUnSET) technique, as modified from studies in C2C12 myoblast cells (Goodman et al., 2011) . Tenocytes were grown to 90% confluence in GM and serum starved in DMEM with 1% AbAm for three hours, followed by treatment with either PD98059, wortmannin, or the protein synthesis inhibitor cycloheximide (R&D Systems) for one hour. Cells were then treated for 30 minutes with 0.25µM puromycin (MilliporeSigma, Burlington, MA, USA), which is a tyrosyl-tRNA analog that is incorporated into newly translated proteins (Goodman and Hornberger, 2013), followed by 100ng/mL of IGF1 for one hour. At the end of the treatment period, tenocytes were scraped from their dishes and homogenized in RIPA buffer (Thermo Fisher Scientific) containing 1% protease and phosphatase inhibitors (Thermo Fisher Scientific).
In Vitro Procollagen I Labeling.
To label procollagen I in proliferating or non-proliferating cells, tenocytes were cultured as described above, incubated with DM overnight, and then treated with either normal DM or DM containing 100ng/mL of IGF1. The thymidine analog EdU was used in lieu of BrdU, as the acid denaturing step required for BrdU detection degraded procollagen I epitopes. Following a 24 hour incubation, fresh media was added along with 10 µM of EdU (Thermo Fisher Scientific) for one hour. Cells were fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and EdU was detected using a Click-iT kit (Thermo Fisher Scientific). Cells were then incubated with antibodies against procollagen I (1:100; sc-30136, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and b-tubulin (1:200; ab6161, Abcam) and secondary antibodies conjugated to AF488 or AF647 (1:300; A11006 and A32733, Thermo Fisher Scientific). Slides were imaged in a LSM 880 laser scanning confocal microscope (Zeiss, Thornwood, NY, USA).
RNA Sequencing and Gene Expression.
RNA was isolated from tendons and cultured tenocytes as previously described (Schwartz et al., 2015; Sugg et al., 2018) . Plantaris tendons or tenocytes were homogenized in QIAzol (Qiagen, Valencia, CA, USA) and RNA was purified with a miRNeasy Micro Kit (Qiagen) supplemented with DNase I (Qiagen). RNA concentration and quality was determined using a NanoDrop 2000 (Thermo Fisher Scientific) and a TapeStation 2200 (Agilent Technologies, Santa Clara, CA, USA).
For RNAseq, 250ng (for whole tendons) or 500ng (for culture cells) was delivered to the University of Michigan Sequencing Core for analysis. Sample concentrations were normalized and cDNA pools were created for each sample, and then subsequently tagged with a barcoded oligo adapter to allow for sample specific resolution. Sequencing was carried out using an Illumina HiSeq 2500 platform (Illumina, San Diego, CA, USA) with 50bp single end reads. Raw RNAseq data was quality checked using FastQC v0.10.0 (Barbraham Bioinformatics, Cambridge, UK). Alignment to the reference genome (mmu10, UCSC), differential expression based on counts per million mapped reads (CPM), and post-analysis diagnostics were carried out using edgeR (Robinson et al., 2010) . A Benjamini-Hochberg false discovery rate (FDR) procedure was applied to correct P values for multiple observations, and these FDR-corrected P values are reported as q values. Sequencing data has been deposited to NIH GEO (GSE131804). 
Biological Pathway Analysis. Expression data from RNAseq measurements was imported into
Ingenuity Pathway Analysis (IPA) software (Qiagen) to assist in predicting cellular and molecular pathways and processes that were altered in response to manipulating IGF1 signaling in tendons.
Western blots.
Western blots were performed as described previously (Gumucio et al., 2019; Sugg et al., 2018) . Tendons and cell pellets were homogenized in ice cold RIPA buffer (Thermo Fisher Scientific) supplemented with 1% protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). A BCA assay (Thermo Fisher Scientific) was used to determine protein concentration. Protein homogenates were diluted in Laemmli's sample buffer, placed in boiling water for two minutes, and 20 µg of protein was separated on either 6% or 12% SDS-PAGE gels depending on the protein of interest. Proteins were transferred to nitrocellulose or PVDF membranes (Bio-Rad) using the Trans-Blot SD semi-dry transfer apparatus (Bio-Rad), blocked with 5% non-fat powdered milk in TTBS solution and incubated with primary antibodies from Cell Signaling (1:1000;
Danvers, MA, USA) against p-IGF1Rβ Y1135 (3918), IGF1Rβ (3025), p-IRS1 S612 (2386), IRS1 (2382), p-Akt T308 (13038), p-Akt S473 (4060), Akt (4691), p-p70S6K T389 (9234), p-p70S6K T421/S424 (9204), p70S6K (2708), p-ERK1/2 T202/Y204 (4370), ERK1/2 (4695), or primary antibodies from Santa Cruz Biotechnology (1:1000) against procollagen type I (sc-30136), or primary antibodies from Abcam (1:1000) against β-tubulin (ab6046), p-ELK S383 (ab34270) or ELK (ab32106), or primary antibodies from MilliporeSigma against pIRS1 Y608 (1:1000) or puromycin (1:2000; 12D10) . Following primary antibody incubation, membranes were rinsed and incubated with HRP-conjugated secondary antibodies (1:10,000; from either AbCam or Cell Signaling). Proteins were detected using Clarity enhanced chemiluminescent reagents (Bio-Rad) and visualized using a digital chemiluminescent documentation system (Bio-Rad). Coomassie staining of membranes was performed to verify equal protein loading. Heatmaps demonstrating the log2 fold change in selected genes from RNAseq that are (C) growth factors, cytokines, or genes involved with activating extracellular ligands, (D) involved in cell proliferation, and tenocyte specification and differentiation, or (E) components or regulators of the extracellular matrix. The fold change value is displayed for each group relative to non-overloaded Scx:IGF1R + (Ctrl) mice. Differences between groups tested using edgeR: a, different (q<0.05) in the respective overloaded group to non-overloaded Scx:IGF1R + mice; b, different (q<0.05) between 7D Scx:IGF1R + and 7D Scx:IGF1R Δ mice; c, different (q<0.05) between 14D Scx:IGF1R + and 14D Scx:IGF1R Δ mice. N=4 mice per group.
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Figure 4. Signaling protein activation and RNAseq in cultured tenocytes treated with IGF1. (A)
Representative western blots for p-IGF1R Y1135 , total IGF1R, IRS1 Y608 , IRS1 S612 , total IRS1, p-ERK1/2 T202/Y204 , total ERK1/2, p-ELK S383 , total ELK, p-Akt T308 , p-Akt S473 , total Akt, p-p70S6K T389 , p-p70S6K T421/S424 , and total p70S6K in cultured tenocytes that were untreated (0 min) or treated with IGF1 for 5, 15, 30, or 60 minutes. (B-E) RNAseq analysis of untreated tenocytes (0h), or tenocytes treated with IGF1 for 1, 2, 6, or 24 hours. The fold change (FC) value is displayed for each group is relative to tenocytes that were not treated with IGF1 (0 hours). (B) Number of genes that were significantly upregulated (red) with a greater than 1.5-fold upregulation and q < 0.05, and significantly downregulated (blue) with a greater than 1.5-fold upregulation and q < 0.05. (C-E) Heatmaps demonstrating the log2 fold change in selected genes from RNAseq that are (C) growth factors, cytokines, or genes involved with activating extracellular ligands, (D) involved in cell proliferation, and tenocyte specification and differentiation, or (E) components or regulators of the extracellular matrix. Differences between groups tested using edgeR: a, different (q<0.05) from 0h IGF1; b, different (q<0.05) from 1h IGF1; c, different (q<0.05) from 2h IGF1; c, different (q<0.05) from 6h IGF1. (C) Representative immunocytochemistry of cultured tenocytes treated with 0ng/mL or 100ng/mL of IGF1 for 24 hours. β-tubulin, green; EdU, red; Procol Iα1, magenta. Scale bar is 50µm in all images. (D) Representative western blot for procollagen type Iα1 (Procol Iα1) in untreated tenocytes (0h) or tenocytes treated with 100ng/mL of IGF1 for 6 or 24 hours. (E) Representative western blot for Procol Iα1 in tenocytes treated with 0ng/mL, 10ng/mL or 100ng/mL of IGF1 for 24 hours.
Figure 7. Protein synthesis in tenocytes treated with IGF1. (A)
Representative western blot for proteins that have incorporated puromycin and (B) quantification of band densitometry for tenocytes that were untreated or were treated with IGF1, IGF1 and cycloheximide, IGF1 and wortmannin, or IGF1 and PD98059. (C) Representative western blots for p-ERK1/2 T202/Y204 , total ERK1/2, p-ELK S383 , total ELK, IRS1 Y608 , IRS1 S612 , total IRS1, p-Akt T308 , and total Akt in untreated cells or in cells treated with IGF1, IGF1 and wortmannin, or IGF1 and PD98059. Differences tested with a one-way ANOVA: a, significantly different (P<0.05) from -IGF1 controls. Coomassie stained membranes are shown as total protein loading controls. Values are mean±CV. N≥4 replicates per group. Tables   Table 1 . Gene enrichment analysis. q-values of select affected or differentially regulated pathways or biological functions that were identified using Ingenuity Pathway Analysis. ND, not significantly different. Values are mean±SD. Differences tested with a two-way ANOVA (α=0.05): a, different (P<0.05) from 7D Scx:IGF1 + ; b, (different (P<0.05) from 7D Scx:IGF1 Δ ; c, different (P<0.05) from 14D Scx:IGF1 + .
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